trymox vet 150 mg/ml injektioneste, suspensio
univet ltd. - amoxicillin trihydrate - injektioneste, suspensio - 150 mg/ml - amoksisilliini
nemavet vet 50 mg/g jauhe
univet ltd. - fenbendazole - jauhe - 50 mg/g - fenbendatsoli
ubroseal vet 2.6 g intramammaarisuspensio
univet ltd. - bismuth subnitrate - intramammaarisuspensio - 2.6 g - muut vetimien ja utareiden hoitoon tarkoitetut valmisteet
chloromed vet 150 mg/g esisekoite lääkerehua varten
univet ltd. - chlortetracycline hydrochloride - esisekoite lääkerehua varten - 150 mg/g - klooritetrasykliini
sunitinib vivanta 50 mg kapseli, kova
vivanta generics s.r.o. - sunitinib malate - kapseli, kova - 50 mg - sunitinibi
sunitinib vivanta 37.5 mg kapseli, kova
vivanta generics s.r.o. - sunitinib malate - kapseli, kova - 37.5 mg - sunitinibi
sunitinib vivanta 25 mg kapseli, kova
vivanta generics s.r.o. - sunitinib malate - kapseli, kova - 25 mg - sunitinibi
sunitinib vivanta 12.5 mg kapseli, kova
vivanta generics s.r.o. - sunitinib malate - kapseli, kova - 12.5 mg - sunitinibi
sunitinib accord
accord healthcare s.l.u. - sunitinibi - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiset aineet - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
sutent
pfizer limited - sunitinibi - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiset aineet - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.